Qualifications: MD MSc PhD FRCP
Professor Sabina Dizdarevic is the current President of the British Nuclear Medicine Society (BNMS) (2025–2027). Previously, she founded and chaired the BNMS Research and Innovation Committee and the Academic–Industry Forum and has also chaired the Society’s Scientific and Education Committee. She has held numerous national leadership roles, promoting innovation, education, research, and workforce development across nuclear medicine.
Professor Dizdarevic has been instrumental in introducing advanced molecular imaging and
targeted radionuclide therapy services at regional, national, and international levels. Together
with colleagues in Brighton, she established one of the world’s first clinical Radium-223
dichloride bone-targeted therapy services in 2014, helping to advance molecular radiotherapy
into routine clinical practice.
She is the UK National Delegate to the European Association of Nuclear Medicine (EANM) and
was appointed to the EANM Member Societies Council in 2026. Her previous national leadership roles include Chair of the Royal College of Physicians Joint Specialty Committee on Nuclear Medicine, Chair of the Intercollegiate Standing Committee on Nuclear Medicine (RCP/RCR), Chair of the ARSAC Research Subgroup, and member of both the UEMS Nuclear Medicine Board and the UK National Specialty Training Committee.
Professor Sabina Dizdarevic graduated in Medicine (MD) from the University of Sarajevo,
completed an MSc in Nuclear Medicine at University College London, where her research focused on Dopamine Transporter (DaTscan) imaging in parkinsonian disorders, and obtained a PhD from the University of Sussex and Brighton investigating the functional molecular imaging of ATP binding cassette (ABC) transporters.
First Sussex patients receive cutting-edge prostate cancer treatments as part of national trial